Immune-Pineal Axis Function in Fibromyalgia

Phase 2

• Conditions: Fibromyalgia
• Interventions: Drug: Melatonin and Placebo; Drug: Melatonin and Amitriptylin; Drug: Amitriptyline and Placebo

• Registration Number: NCT02041455
• Lead Sponsor: Hospital de Clinicas de Porto Alegre

Brief Summary

Fibromyalgia is a common condition in clinical medical practice, characterized by diffuse musculoskeletal pain. Sleep disorders, chronic fatigue, depression, intestinal disorders and headache are also commonly associated with the syndrome .

Although the etiology of this syndrome is not well defined yet, it means involve multiple mechanisms, including low levels of serotonin, increased substance P in cerebrospinal fluid and altered circadian variation in sympathetic - parasympathetic balance, consistent with changes in sympathetic hyperactivity at night .

The immune - pineal system, formed by the integration of the adrenergic and immune systems pineal gland, appears to be involved in the genesis of the dysfunctions found in fibromyalgia. Melatonin is secreted by the pineal gland and has promoter activity of sleep. Studies show that melatonin and its precursors , serotonin and tryptophan are reduced in patients with fibromyalgia.

The present study aims to evaluate the relationship of immune - pineal system in the process of fibromyalgia , since dysfunction of this axis appears to govern the cascading events that participate in the pathophysiological process of this disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06
• Status Verified: 2014-01
• Primary Completion: 2014-01
• Study First Submitted: 2014-01-16
• Study First Submitted QC: 2014-01-17
• Last Update Submitted: 2014-01-17
• Study First Posted: 2014-01-22
• Last Update Posted: 2014-01-22
• Study Completion: 2014-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 66

Inclusion Criteria

• Women 18-65 years old
• Fibromyalgia according to the criteria of the American College of Rheumatology (Wolfe 2010)
• Sign the informed consent
• Patients can take medication for chronic pain ( antidepressants , antiepileptics, for example), since there are at least two months

Exclusion criteria:

• patients who did not understand the Portuguese
• diagnosis of malignancies, severe psychiatric disorders , sleep disorders not related to fibromyalgia (apnea , sleepwalking , restless leg syndrome), Alzheimer's disease or any disease (rheumatologic, neurological, etc.) that can modify the evaluations or outcomes
• alcohol abuse or drug addiction
• patients who are performing acupuncture
• BMI greater than 35 ( BMI = body mass index) .
• Patients with history of allergy to amitriptyline or/and melatonin or any other contraindication for the use of these drugs

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Melatonin and Placebo	Melatonin and Placebo	Melatonin 10mg and placebo, once in the evening, for 6 weeks.
Melatonin and Amitriptylin	Melatonin and Amitriptylin	Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
Amitriptyline and placebo	Amitriptyline and Placebo	Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in pain on Fibromyalgia Impact Questionnaire (FIQ) at week 6	Baseline, week 6
Change from Baseline in Pain Pressure Threshold (PPT) at week 6	Baseline, week 6	Pain Pressure Threshold by Fischer algometer on the tender points.
Change from Baseline Brain-derived neurotrophic factor at week 6	Baseline, week 6

Secondary Outcome Measures

Name	Time	Method
Change from Baseline of the Pittsburgh Sleep Quality Index (PSQI) at week 6	Baseline, week 6
Change from Baseline of the Pain Catastrophizing Scale at week 6	Baseline; week 6	Catastrophic thinking related to pain

Trial Locations

Locations (1)

Hospital de Clínicas de Porto Alegre; 🇧🇷 Porto Alegre, RS, Brazil